The Bayesian basket design for genomic variant-driven phase II trials.

abstract：:The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...

journal_title：Seminars in oncology

authors： Capoluongo E,Ellison G,López-Guerrero JA,Penault-Llorca F,Ligtenberg MJL,Banerjee S,Singer C,Friedman E,Markiefka B,Schirmacher P,Büttner R,van Asperen CJ,Ray-Coquard I,Endris V,Kamel-Reid S,Percival N,Bryce J,Röthlisbe

更新日期：2017-06-01 00:00:00

abstract：:Gemcitabine, a novel nucleoside analog, shows reproducible response rates of 20% and above in single-agent studies in non-small cell lung cancer. In the phase II studies reported, chemotherapy-naive patients received gemcitabine (starting doses, 800 to 1,250 mg/ m2) as a single agent on days 1, 8, and 15 of a 28-day c...

journal_title：Seminars in oncology

authors： Le Chevalier T

更新日期：1996-10-01 00:00:00

abstract：:Almost 125 years after the first documented case, pulmonary metastasectomy is still poorly understood. No other organ is subject to the wide histologic variety of metastatic insults, and this fact has complicated a complete exposition of when pulmonary metastasectomy may be beneficial. Many physicians still consider p...

journal_title：Seminars in oncology

authors： Sternberg DI,Sonett JR

更新日期：2007-06-01 00:00:00

abstract：:Since its approval in 2011 for patients with recurrent glioblastoma (GBM), physicians have responded positively to the non-invasive nature of the NovoTTF-100A System device (NovoCure Ltd, Haifa, Israel), citing significantly less toxicity and a better quality of life profile compared to available conventional therapie...

journal_title：Seminars in oncology

authors： Butowski N,Wong ET,Mehta MP,Wilson LK

更新日期：2013-12-01 00:00:00

abstract：:Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts. Clinical management of HCM primarily consists of intravenous rehydration therapy combined with pharmaceutical agents that decrease osteoclast activity. Several generations...

journal_title：Seminars in oncology

authors： Berenson JR

更新日期：2002-12-01 00:00:00

abstract：:First-line therapy for men with metastatic or recurrent prostate cancer following definitive local therapy is medical or surgical castration. Though effective initially in most patients, the majority of tumors develop castration resistance, necessitating the addition of further therapy. The historic treatment paradigm...

journal_title：Seminars in oncology

authors： Hoffman-Censits J,Fu M

更新日期：2013-06-01 00:00:00

abstract：:Therapy for metastatic breast cancer can palliate disease and prolong life, but cannot cure. New drugs will be required if this is to change. Cisplatin and its analogue carboplatin offer new approaches to the treatment of metastatic breast cancer. Cisplatin has significant single-agent, front-line activity in metastat...

journal_title：Seminars in oncology

authors： Sledge GW Jr

更新日期：1992-02-01 00:00:00

abstract：:A substantial proportion of patients with squamous cell carcinoma of the head and neck have extensive locoregional disease at presentation. While extensive surgical procedures may completely eradicate local disease with acceptable morbidity for smaller tumors, in patients with stage III and IV disease, high local rela...

journal_title：Seminars in oncology

authors： Eisenberger M,Jacobs M

更新日期：1992-08-01 00:00:00

abstract：:The benefits of radiation therapy (RT) as part of a treatment regimen for cancer must be weighed against the potential risk of harm to the patient and in the pregnant patient, the risk to the developing fetus. Information necessary for determining the potential effects of RT on the developing fetus include the gestati...

journal_title：Seminars in oncology

authors： Greskovich JF Jr,Macklis RM

更新日期：2000-12-01 00:00:00

abstract：:Cancer clinical trials represent an important option for patients with a diagnosis of cancer and the clinician-investigators involved in their care who seek options for their disease. For all who are impacted by cancer, these studies offer opportunities for greater learning. Conducting these important studies involves...

journal_title：Seminars in oncology

authors： Schiller SJ,Shannon C,Brophy MT,Denicoff AM,Good MJ,Prindiville SA,Huang GD

更新日期：2019-01-01 00:00:00

abstract：:Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, often presenting with distant metastasis. While controversy exists regarding the actual incidence of the disease, there is agreement that IBC causes a disproportionate number of breast cancer deaths. Those with typical IBC symptoms face a h...

journal_title：Seminars in oncology

authors： Mason G,Johnson O

更新日期：2008-02-01 00:00:00

abstract：:Acute and chronic graft-versus-host disease (GvHD) remain major obstacles to successful allogeneic hematopoietic stem cell transplantation, contributing substantially to morbidity and non-relapse mortality. Better understanding of the immunopathophysiology of GvHD has identified a number of targets for intervention. A...

journal_title：Seminars in oncology

authors： Bruner RJ,Farag SS

更新日期：2003-08-01 00:00:00

abstract：:Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes ...

journal_title：Seminars in oncology

authors： Krag DN,Weaver DL

更新日期：2002-06-01 00:00:00

abstract：:The American Joint Committee on Cancer (AJCC) recently launched a new staging system for cutaneous melanoma that was based on clinical experience with a large number of patients treated in major centers worldwide. As this system includes various histopathologic parameters of the primary melanoma and of melanoma metast...

journal_title：Seminars in oncology

authors： Ruiter DJ,Spatz A,van den Oord JJ,Cook MG,Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group.

更新日期：2002-08-01 00:00:00

abstract：:Because patients with metastatic bone disease suffer a significant burden from their illness and from anticancer treatments, it is therefore important to minimize the side effects of bisphosphonates. The intravenous bisphosphonates, zoledronic acid and pamidronate, have tolerability issues that include a flu-like synd...

journal_title：Seminars in oncology

authors： Body JJ,Diel I,Bell R

更新日期：2004-10-01 00:00:00

abstract：:Developments in the treatment of extensive small cell lung cancer have proven effective in palliative management but have not yielded improvements in the cure rate for this disease. Strategies involving dose escalation of chemotherapy, including de novo and late intensification dose escalation and dose escalation with...

journal_title：Seminars in oncology

authors： Comis RL

更新日期：1992-12-01 00:00:00

abstract：:A phase II study was performed to investigate the tolerance and efficacy of the combination of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and gemcitabine in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). To date, 24 patients (five with stage IIIB and 19 with stage IV NSCLC...

journal_title：Seminars in oncology

authors： Georgoulias V,Kourousis C,Androulakis N,Kakolyris S,Dimopoulos MA,Bouros D,Papadimitriou C,Hatzakis K,Heras P,Kalbakis K,Kotsakis T,Vardakis N,Meramveliotakis N,Hatzidaki D

更新日期：1997-08-01 00:00:00

abstract：:Although more common in developing countries, over 11,000 deaths will occur in the United States from head and neck cancer in 2004. Squamous cell carcinomas account for the vast majority of cases in the United States and the majority of these are related to exposure to tobacco and alcohol. Newer data suggest a genetic...

journal_title：Seminars in oncology

authors： Sturgis EM,Wei Q,Spitz MR

更新日期：2004-12-01 00:00:00

abstract：:Despite marked improvements in the treatment options available for patients with lung cancers, more than 85% of patients ultimately relapse and die of their disease. Among the most auspicious of new agents available to treat lung cancers, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) also has been th...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1996-12-01 00:00:00

abstract：BACKGROUND:Patients with severe renal impairment or undergoing hemodialysis are usually excluded from clinical trials. Available data regarding safety and activity of systemic therapies (ST) in hemodialyzed patients are scarce. METHODS:Clinical data were searched through PubMed database until April 2020 according to P...

journal_title：Seminars in oncology

authors： Klajer E,Garnier L,Goujon M,Schlurmann-Constans F,Mery B,Nguyen Tan Hon T,Mouillet G,Calcagno F,Thiery-Vuillemin A

更新日期：2020-01-01 00:00:00

abstract：:While cancers of the upper gastrointestinal tract are related by location, they have distinct clinical and molecular characteristics. This review will focus on the molecular biology of esophageal adenocarcinoma (EAC) of which alterations in p53, overexpression of cyclin D1, loss of p16, and aneuploidy have been best c...

journal_title：Seminars in oncology

authors： Lin J,Beerm DG

更新日期：2004-08-01 00:00:00

abstract：:In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

journal_title：Seminars in oncology

authors： Chmura SJ,Milano MT,Haraf DJ

更新日期：2004-12-01 00:00:00

abstract：:Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA ...

journal_title：Seminars in oncology

authors： Ryan CW,Stadler WM,Vogelzang NJ

更新日期：2001-08-01 00:00:00

abstract：:Optimal management of cancer today requires a thorough and up-to-date understanding of cancer cell kinetics and biochemistry. This report reviews the history and current standards in these fields and how they affect the contemporary approach to breast cancer management. Also outlined are recommended avenues for future...

journal_title：Seminars in oncology

authors： Norton L

更新日期：1999-02-01 00:00:00

abstract：:Intraoperative lymphatic mapping and selective lymphadenectomy for solid malignancies is a novel technique, having been introduced into surgical practice in the last 12 years. Dissemination of this technique among surgeons has followed a course similar to that found with the introduction of new laparoscopic techniques...

journal_title：Seminars in oncology

authors： Wilke LG

更新日期：2004-06-01 00:00:00

abstract：:Compelling data implicate angiogenesis and tumor-associated neovascularization as a central pathogenic step in the process of tumor growth, invasion, and metastasis. These complex processes involve multiple steps and pathways dependent on the local balance between positive and negative regulatory factors, as well as i...

journal_title：Seminars in oncology

authors： Pluda JM

更新日期：1997-04-01 00:00:00

abstract：:Over the past 5 years there has been a renewed interest in the use of monoclonal antibodies and immunoconjugates in the treatment of nonhematologic malignancies. This enthusiasm has stemmed from advances in recombinant technology allowing for the production of chimeric and humanized antibodies, from Food and Drug Admi...

journal_title：Seminars in oncology

authors： Murray JL

更新日期：2000-12-01 00:00:00

abstract：:Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1989-08-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

journal_title：Seminars in oncology

authors： Manegold C

更新日期：1998-08-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00